A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND

被引：0
|
作者：
O'Shaughnessy, Joyce
Basho, Reva
Lustberg, Maryam
Lyman, Gary H.
Prahladan, Manoj
James, Gareth D.
Varghese, Della
Lujan, Flavia
Tesch, Hans
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-17-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-17-02
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Nie, Tina
    Blair, Hannah A.
    TARGETED ONCOLOGY, 2023, 18 (03) : 463 - 470
  • [2] Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer
    Shimomura, Akihiko
    Takano, Toshimi
    Takahashi, Shunji
    Sagara, Yasuaki
    Watanabe, Junichiro
    Tokunaga, Eriko
    Shinkai, Tetsu
    Kamio, Takahiro
    Kikumori, Kunika
    Kamiyama, Emi
    Fujisaki, Yoshihiko
    Saotome, Dan
    Yamashita, Toshinari
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (01) : 160 - 169
  • [3] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Tina Nie
    Hannah A. Blair
    Targeted Oncology, 2023, 18 : 463 - 470
  • [4] The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with carcinomatosis
    Batista, Marta Vaz
    Perez-Garcia, Jose Manuel
    Garrigos, Laia
    Garcia-Saenz, Jose Angel
    Cortez, Patricia
    Racca, Fabricio
    Blanch, Salvador
    Ruiz-Borrego, Manuel
    Fernandez-Ortega, Adela
    Fernandez Abad, Maria
    Iranzo, Vega
    Gion, Maria
    Martrat, Griselda
    Alcala-Lopez, Daniel
    Perez-Escuredo, Jhudit
    Sampayo-Cordero, Miguel
    Llombart-Cussac, Antonio
    Braga, Sofia
    Cortes, Javier
    MED, 2025, 6 (01):
  • [5] Concurrent Use of Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer
    Bouziane, Jihane
    Loap, Pierre
    Cao, Kim
    Allali, Sofiane
    Gounane, Yacine
    Loganadane, Gokoulakrichenane
    Escalup, Laurence
    Pierga, Jean-Yves
    Kirova, Youlia
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (12): : 580 - 584
  • [6] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [7] Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study
    Sang, Die
    Su, Yanfang
    Zhang, Yurong
    Guan, Yanfeng
    Fan, Shanmin
    Zhang, Jintao
    Zheng, Lijun
    Wang, Yanling
    Guo, Ying
    Lei, Zixuan
    Li, Man
    Yuan, Peng
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [8] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
    Ferhanoglu, Burhan
    Atesoglu, Elif Birtas
    Ozbalak, Murat
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12) : 1147 - 1147
  • [9] Trastuzumab Deruxtecan in cerebral metastatic HER2-positive Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (04) : 354 - 354
  • [10] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
12345